Back to results
US 2023/0417763 A1Published application
Method of determining toxicity of an immunomodulatory drug for use in humans
AssigneeThe Jackson Laboratory
InventorsJames Keck, Chunting Ye
Life of this patent
Estimating the term…
Abstract
Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
Claims21
1-53. (canceled)
A method for assessing immune toxicity of an immunomodulatory agent, the method comprising:
- (a) administering human peripheral blood mononuclear cells (PBMCs) to an immunodeficient mouse that has been subjected to myeloablation;
- (b) administering an immunomodulatory agent to the immunodeficient mouse;
- and
- (d) measuring blood concentration of a human cytokine selected from interferon-gamma (IFN-γ), interleukin (IL)-10, IL-6, IL-2, IL-4, and tumor necrosis factor alpha (TNFα) in a sample from the immunodeficient mouse before the mouse develops a symptom of graft versus host disease (GVHD), wherein blood concentration of the cytokine equal to or above a threshold concentration value is indicative of immune toxicity of the immunomodulatory agent.
1 more element
A method for assessing immune toxicity of an immunomodulatory agent, the method comprising:
- (a) administering human peripheral blood mononuclear cells (PBMCs) to an immunodeficient mouse that has been irradiated;
- (b) administering an immunomodulatory agent to the immunodeficient mouse fewer than 8 days after the administering human PBMCs;
- and
- (d) measuring blood concentration of a human cytokine selected from interferon-gamma (IFN-γ), interleukin (IL)-10, IL-6, IL-2, IL-4, and tumor necrosis factor alpha (TNFα) in a sample from the immunodeficient mouse before the mouse develops a symptom of graft versus host disease (GVHD), wherein the symptom of GVHD is significant weight loss, and
- wherein blood concentration of the cytokine equal to or above a threshold concentration value is indicative of immune toxicity of the immunomodulatory agent.
2 more elements
Dependencies are inferred from the claim text.